BioSig technologies

NASDAQ: BSGM

BioSig Technologies, Inc. is a medical technology company that is developing a proprietary biomedical signal processing platform initially aimed at addressing unmet clinical needs within the rapidly growing $4.6 billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles -based BioSig is preparing to commercialize its PURE EP™ System. PURE EP™ is a signal acquisition and processing system designed to assist electrophysiologists in making clinical decisions in real-time to help identify areas of tissue that create a heart rhythm disturbance (arrhythmia). PURE EP™ is designed to support catheter ablation cases, working in parallel with existing recording and mapping systems. BioSig's goal is to improve the standards of care in electrophysiology and increase the number of patients who can have their condition successfully treated during the first procedure.

PURE EP™ System

Key Growth Drivers

1) **Advanced Technology** — The non-invasive PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. The system is indicated for use under the supervision of licensed healthcare practitioners who are responsible for interpreting the data. The PURE EP System aims to minimize noise and artifacts, and acquire high-fidelity cardiac signals. Improving cardiac signals may potentially increase the diagnostic value of these signals, thereby possibly improving accuracy and efficiency of the EP studies and related procedures. The PURE EP™ System received FDA 510(k) clearance in August 2018.

2) **Market Opportunity** — Market Research Engine states the global electrophysiology (EP) device market is expected to exceed more than US $8.5 billion by 2024 and is growing at a compound annual growth rate (CAGR) of 10.6%. The Company also operates within the rapidly emerging field of bioelectronic medicine, estimated at $3.75 billion in 2017 with projected annual growth of 14.2%.

3) **KOL Support** — The Company had achieved proof of concept validation through UCLA, and performed thirteen pre-clinical studies at Mayo Clinic, MN and one study at Mt Sinai, NY to date. The Company's Scientific Advisory Board is led by Dr. Andrea Natale, Texas Cardiac Arrhythmia Institute and Dr. Samuel Asirvatham, Mayo Clinic—both institutes will be performing First-In-Human Studies with PURE EP™ in 2019. BioSig also collaborates with other centers of excellence to refine and, ultimately, commercialize its novel information system.

Recent Highlights

- **Mayo Clinic to Launch PURE EP™ First-in-Human Studies**
- **Texas Cardiac Arrhythmia Institute to Install PURE EP™ System for First-In-Human Studies**
- **Announced Commencement of Trading on Nasdaq Capital Market**
- **Announced 1-for-2.5 Reverse Stock Split**
- **Received FDA 510(k) Clearance for PURE EP™ System**
- **Ranked Top 50 for The Silicon Review's Innovative Companies to Watch in 2018**

Market Snapshot
NASDAQ: BSGM

Price (12/19/18)	$4.55*
Average Volume (90 day)	55,770
52-Wk. Range	$3.21 - $7.88
Float	12.54 M
Shares Outstanding	16.87 M
Market Cap	$76.76 M

***1-for-2.5 reverse stock split adjusted common stock effective September 11, 2018**

BioSig Technologies, Inc.
12424 Wilshire Blvd. Suite 745
Los Angeles, CA 90025
(512) 329-2643
www.biosig.com

Contact:
Kenneth L. Londoner
Phone: +1-203-644-5200
klondoner@biosig.com

IRTH Communications
Phone: +1-866-976-4784
BSGM@irthcommunications.com

Investment Catalysts

PURE EP™ System

Proprietary Hardware and Software with Advanced Signal Processing Capabilities:

- To Improve Signal Clarity Through Reduction of 'Noise' and Artifacts
- To Minimize Need for Repeat Procedures
- To Preserve Important Clinical Information
- To Shorten Procedure Times
- To Increase Confidence in Performing Complex Ablations



Global EP Market—10.6% Growth from 2016-2024 reaching $8.5B by 2024

- Global Ablation: 865,000 patients in 2015 to 1,350,000 in 2020.
- US Procedure Growth: 11% annual rate, from 250,000 in 2015 to 422,000 in 2020. Accompanied by an 11.7% growth in revenues, from $1.85 billion in 2015 to $3.220 billion in 2020.
- The FDA (www.fda.gov) presented at the Heart Rhythm Society 2017 and spoke of the importance of technological innovation in the EP field.



Proven Team

BioSig is comprised of a stellar cast of a proven management team with a world-class Scientific Advisory Board and a premier Board of Directors with high levels of inside equity ownership.

BioSig brought together leading physicians, executives and engineering experts from leading medical centers of excellence, healthcare programs, Fortune 500 Companies and elite educational institutions including Mayo Clinic, Mount Sinai Medical Center, UCLA, Johnson & Johnson, Nasdaq and Prudential Securities.

Kenneth L. Londoner, Chairman & CEO, has a wealth of knowledge and experience that spans many decades and includes founding, running, and serving as Director to a number of life science companies. Mr. Londoner began his career with J. & W. Seligman & Co., Inc., a leading institutional money management firm where he rose from research analyst to managing $3.5 billion in mutual funds, pension funds, and international assets. Steve Chaussy, CFO has acted as a consultant for small publicly traded entities with a special emphasis towards SEC reporting and compliance; and served as CFO for a large private distribution and wholesaling company, where he gained international experience.

Their many accomplishments and years of experience of the management team, as well as the Board of Directors and Scientific Advisory Board, is unmatched and provides BioSig a clear advantage in the market.

Investment Highlights

- 2018—raised $13.5 million to date
- 10-year Strategic Collaboration with Mayo Clinic
- Core competency in Basic Science, Capital Markets and Capital Architecture
- IP Strategy Led by Sherpa Technology Group and Sterne Kessler Goldstein & Fox
- FDA clearance achieved; CE Mark—2019
- Proven Management Team, Board of Directors and Scientific Advisory Board
- Global and Growing Addressable Market
- Operates Within Rapidly Emerging Field of Bioelectronic Medicine
- High-Growth Sector Earns Innovation Premium, Aggressive M&A

BioSig is collaborating with leading EPs from:

MAYO CLINIC · UCLA Health · TEXAS CARDIAC ARRHYTHMIA · BRIGHAM AND WOMEN'S HOSPITAL · University Hospitals Case Medical Center · Mount Sinai

Current Cardiac Arrhythmia Epidemic (1 in 18 or 14.4M Americans)

Two of the most prevalent and potentially deadly types of arrhythmias today are Atrial Fibrillation (AF) and Ventricular Tachycardia (VT). Ventricular arrhythmias account for approximately 450,000 sudden deaths per year in the United States alone. Catheter ablation is fast becoming a first line therapy, driving demand for improved technologies. AF is the most common arrhythmia affecting 33.5 million people worldwide, with as many as 6.1 million people in the U.S. now and expected 8-12 million by 2050. AF increases the risk of stroke 4x to 5x and contributes to ~750,000 hospitalizations per year. The direct cost of AF is approximately $6B annually; adding other indirect costs brings AF total cost to $26B.

Management

Kenneth L. Londoner, MBA, Founder, Chief Executive Officer, Chairman, Director
Endicott Management Partners; J & W Seligman & Co; Director: Alliqua

Steve Chaussy, CPA, Chief Financial Officer
Liberski Inc; Anna & Co; Penske Truck Leasing, Ford, Hogg & Cobbe

Tiffini Wittwer, Chief Regulatory & Compliance Officer
Trice Medical; Embrella Cardiovascular; Cardica

Natasha Drapeau, Executive Vice President
IG Group Plc, London, UK; Augeous Consulting, Geneva, Switzerland

Amy Scott, VP – Strategic Partnerships
Biosense Webster (Johnson & Johnson)

Lora Mikolaitis, VP – Administration
Miko Consulting Group, Inc.

Directors

Roy T. Tanaka, Director
Former Pres: Biosense Webster/J&J; Dir: Tomo Therapy, Volcano Corp, Advanced Cardiac Therapeutics, VytronUS, Coherex Medical

Donald E. Foley, Director
CEO & Chair: Wilmington Trust; Sr VP, Treas & Dir: ITT Corp; Asst Treas: International Paper Co.

David Weild IV, MBA, Director
Current Chairman & CEO; Weild & Co.; Vice Chairman: NASDAQ; Head of Corporate Finance & Equity Markets: Prudential Securities

Patrick J. Gallagher, MBA, Director
Mg Dir: Laidlaw & Co.; Kinex Pharmaceuticals; Director: Cingulate Therapeutics, BDR Research Group, GC Capital Partners, Kidder Peabody

Jeffrey F. O'Donnell, Sr., Director
Current CEO, Director: Trice Medical; Current Chair: SpectraWave; Director: AdvaMed Accel; Founder: Embrella Cardiovascular (sold to Edwards Lifesciences); CEO: PhotoMedex, Radiance Medical (Cardiovascular Dynamics), Kensey Nash; Sales/Mktg Mngt: Boston Scientific, Guidant, J&J; Former Director: Cardiac Science, Endologix

Seth H. Z. Fischer, Director
Former CEO & Dir: Vivus, Inc; Former WW Chairman: J&J, Cardiovascular

Andrew Filler, Director
Current Partner & General Counsel: Sherpa Technology Group, Nanosys; IP Counsel: Previvo Genetics; Board: Aira Technologies. Former: Caliper Life Sciences (sold to Perkin Elmer), Weil, Gotshal & Manges

Analyst Coverage
Laidlaw & Co (UK) Ltd.
ROTH Capital Partners
Chardan Capital Markets, LLC.